MX2021013970A - Formas cristalinas de n-[4-(clorodifluorometoxi)fenil]-6-[(3r)-3-h idroxipirrolidin-1-il]-5-(1h-pirazol-5-il)piridina-3-carboxamida. - Google Patents

Formas cristalinas de n-[4-(clorodifluorometoxi)fenil]-6-[(3r)-3-h idroxipirrolidin-1-il]-5-(1h-pirazol-5-il)piridina-3-carboxamida.

Info

Publication number
MX2021013970A
MX2021013970A MX2021013970A MX2021013970A MX2021013970A MX 2021013970 A MX2021013970 A MX 2021013970A MX 2021013970 A MX2021013970 A MX 2021013970A MX 2021013970 A MX2021013970 A MX 2021013970A MX 2021013970 A MX2021013970 A MX 2021013970A
Authority
MX
Mexico
Prior art keywords
crystalline forms
chlorodifluoromethoxy
hydroxypyrrolidin
pyrazol
pyridine
Prior art date
Application number
MX2021013970A
Other languages
English (en)
Inventor
Arnaud Grandeury
Stephanie Kay Dodd
Evgenia Rousaki
Emmanuel Suffert
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2021013970A publication Critical patent/MX2021013970A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención describe formas cristalinas específicas de N-[4-(Clorodifluorometoxi)fenil]-6-[(3R)-3-hidroxipirrolidin-1-il ]-5-(1H-pirazol-5-il)piridina-3-carboxamida. La presente invención además se refiere a métodos para preparar dichas formas cristalinas, a composiciones farmacéuticas que comprenden dichas formas cristalinas, y métodos de uso de dichas formas cristalinas y composiciones farmacéuticas para tratar enfermedades.
MX2021013970A 2019-05-16 2020-05-15 Formas cristalinas de n-[4-(clorodifluorometoxi)fenil]-6-[(3r)-3-h idroxipirrolidin-1-il]-5-(1h-pirazol-5-il)piridina-3-carboxamida. MX2021013970A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962848857P 2019-05-16 2019-05-16
US201962949599P 2019-12-18 2019-12-18
PCT/IB2020/054628 WO2020230099A1 (en) 2019-05-16 2020-05-15 Crystalline forms of n-[4-(chlorodifluoromethoxy)phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-5-yl)pyridine-3-carboxamide

Publications (1)

Publication Number Publication Date
MX2021013970A true MX2021013970A (es) 2022-01-04

Family

ID=70775449

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013970A MX2021013970A (es) 2019-05-16 2020-05-15 Formas cristalinas de n-[4-(clorodifluorometoxi)fenil]-6-[(3r)-3-h idroxipirrolidin-1-il]-5-(1h-pirazol-5-il)piridina-3-carboxamida.

Country Status (13)

Country Link
US (3) US11407735B2 (es)
EP (1) EP3969117A1 (es)
JP (1) JP2022532404A (es)
KR (1) KR20220009414A (es)
CN (1) CN114144232A (es)
AU (1) AU2020276701B2 (es)
BR (1) BR112021022712A2 (es)
CA (1) CA3139812A1 (es)
CL (1) CL2021003011A1 (es)
IL (1) IL287995A (es)
MX (1) MX2021013970A (es)
TW (1) TW202110823A (es)
WO (1) WO2020230099A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4096790A1 (en) 2020-01-28 2022-12-07 Teva Pharmaceuticals International GmbH Solid state forms of asciminib and processes for the preparation thereof
WO2022206937A1 (zh) * 2021-04-01 2022-10-06 苏州晶云药物科技股份有限公司 一种吡唑取代的烟酰胺类化合物的盐酸盐新晶型及其制备方法
CN114369085B (zh) * 2021-12-27 2023-01-03 武汉九州钰民医药科技有限公司 盐酸Asciminib的制备方法
WO2024100212A1 (en) 2022-11-10 2024-05-16 Synthon B.V. Crystalline form of asciminib hydrochloride

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2930501A (en) * 2000-01-07 2001-07-24 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
CA2871715A1 (en) 2012-05-15 2013-11-21 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
MA37519B1 (fr) * 2012-05-15 2017-03-31 Novartis Ag Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
EP3120851A1 (en) 2015-07-21 2017-01-25 Pangaea Biotech S.L. 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
US9931342B2 (en) 2016-02-02 2018-04-03 Duke University Compositions and methods for the treatment of cancer
EP3292870A1 (en) 2016-09-08 2018-03-14 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Fibronectin for use in the treatment of leukemia
CN109715616A (zh) 2016-09-27 2019-05-03 诺华股份有限公司 用于结晶有机化合物的表面活性剂体系
CN111556747B (zh) 2017-10-27 2023-11-17 索尼克马斯特有限公司 用于调节肌肉功能的dux4诱导的抑制剂
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof

Also Published As

Publication number Publication date
US20200361904A1 (en) 2020-11-19
AU2020276701A8 (en) 2022-05-12
US11407735B2 (en) 2022-08-09
US20230074064A1 (en) 2023-03-09
CA3139812A1 (en) 2020-11-19
WO2020230099A1 (en) 2020-11-19
KR20220009414A (ko) 2022-01-24
BR112021022712A2 (pt) 2022-03-29
JP2022532404A (ja) 2022-07-14
AU2020276701A1 (en) 2022-01-06
TW202110823A (zh) 2021-03-16
US20230089503A1 (en) 2023-03-23
CN114144232A (zh) 2022-03-04
AU2020276701B2 (en) 2023-11-23
CL2021003011A1 (es) 2022-09-09
IL287995A (en) 2022-01-01
EP3969117A1 (en) 2022-03-23

Similar Documents

Publication Publication Date Title
MX2021013970A (es) Formas cristalinas de n-[4-(clorodifluorometoxi)fenil]-6-[(3r)-3-h idroxipirrolidin-1-il]-5-(1h-pirazol-5-il)piridina-3-carboxamida.
AU2018236800B2 (en) DNA-PK inhibitors
PH12019501985A1 (en) Fused imidazo-piperidine jak inhibitors
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
MY195427A (en) Jak Kinase Inhibitor Compounds for Treatment of Respiratory Disease
EA201991884A2 (ru) Ингибиторы g12c kras
CR20200617A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
SG10201811384TA (en) Mnk inhibitors and methods related thereto
NZ766570A (en) Pyrimidinones as factor xia inhibitors
EA201690752A1 (ru) Ингибиторы g12c kras
PH12020500343A1 (en) Pyruvate kinase activators for use in treating blood disorders
PH12019502425A1 (en) Crystalline forms of a jak inhibitor compound
NZ746950A (en) Heterocyclic gpr119 agonist compounds
MX2018013227A (es) Formas cristalinas de n-[2-(3-hidroxi-3-metilbutil)-6-(2-hidroxipr opan-2-il)-2h-indazol-5-il]-6-(trifluorometil)-piridin-2-carboxam ida.
SG10201805392YA (en) 1,2,4-triazine-6-carboxamide kinase inhibitors
PH12019500497A1 (en) Heteroaryl carboxamide compounds as inhibitors of ripk2
MX2017014715A (es) Benzamidas sustituidas y metodos para utilizarlas.
MY174239A (en) Oxazolidin-2-one-pyrimidine derivatives
MX2018001979A (es) (s,e) -3- (6-aminopiridin-3-il) -n- ( (5- (4- (3-fluoruro-3 metilpirrolidin-1-carbonil) fenil) -7- (4 fluorofenil) benzofuran-2-il)metil)acrilamida para el tratamiento del cancer.
MX2018007219A (es) Metodos para preparacion de compuestos heterociclicos de 1,3-benzodioxol.
MX2019013979A (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
MX2014005715A (es) N-metil-2-[3-((e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]- benzamida para el tratamiento de leucemia mielogenosa cronica.
MX2015013414A (es) N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa.
PH12017500089A1 (en) Aldosterone synthase inhibitors
MX2016010272A (es) Derivado de indolona sustituido por pirrol, metodo de preparacion del mismo, composicion que comprende el mismo y uso del mismo.